// App-Quantinova.ai

1773 : HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer

Researchers

Presenter

  • Bryan Lemon

Principal Investigators

  • Wade Aaron

  • Richard Austin

  • Patrick Baeuerle

  • Manasi Barath

  • Adrie Jones

  • Susan D. Jones

  • Kathryn Kwant

  • Che-Leung Law

  • Anna Muchnik

  • Kenneth Sexton

  • Laurie Tatalick

  • Holger Wesche

  • Timothy Yu

Medical Centers

  • CytomX Therapeutics, South San Francisco, CA

  • MPM Capital, Cambridge, MA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Folate Hydrolase 1

  • Human albumin

Drug/Treatment

  • Enzalutamide

  • CB-7598

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved